← back to search

Shiladitya Sengupta

Brigham and Women's Hospital · US
Area of research
Biomaterials · Biomedical Engineering
Research interest
Research interests include Nanoparticle-Based Drug Delivery, Nanoplatforms for cancer theranostics, Immunotherapy and Immune Responses, and Cancer Cells and Metastasis.
h-index
39
citations
6,363
works
168
NIH funding
primary concept
email

Recent publications

Recommendations for mitochondria transfer and transplantation nomenclature and characterization
Nature Metabolism 2025cited by 110position: middledoi
Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy
Cell 2024cited by 191position: middledoi
An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy
Proceedings of the National Academy of Sciences 2024cited by 23position: middledoi
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells
Nature Nanotechnology 2021cited by 381position: lastdoi
Engineered cell-laden alginate microparticles for 3D culture
Biochemical Society Transactions 2021cited by 29position: middledoi
Human Nonalcoholic Steatohepatitis on a Chip
Hepatology Communications 2020cited by 90position: middledoi
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Advanced Science 2020cited by 51position: middledoi
Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling
Advanced Healthcare Materials 2019cited by 209position: middledoi
Reporter nanoparticle that monitors its anticancer efficacy in real time
Proceedings of the National Academy of Sciences 2016cited by 76position: lastdoi
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Nature Communications 2015cited by 307position: middledoi
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition
Nature Communications 2015cited by 286position: lastdoi
Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype
Nature Communications 2015cited by 85position: lastdoi
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
Neuro-Oncology 2014cited by 166position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Hae Lin Jang · Massachusetts Institute of Technology4 papers (2020–2024) · 3 papers (2015–2021)Bumseok Namgung · National University of Singapore3 papers (2020–2024) · 2 papers (2015–2015)Peyton Tebon · University of California, Los Angeles2 papers (2019–2020)Wujin Sun · Virginia Tech2 papers (2019–2020) · 2 papers (2015–2016)Aaron Goldman · Massachusetts Institute of Technology2 papers (2015–2016)Ashish Kulkarni · Massachusetts Institute of Technology2 papers (2015–2016) · 2 papers (2021–2024) · 2 papers (2016–2024)Jayanta Mondal · The University of Texas Health Science Center at Houston1 papers (2021–2021)Taewoo Lee · National University of Singapore1 papers (2024–2024)Ali Khademhosseini · Terasaki Foundation1 papers (2020–2020)Jixiang Zhu · Second Affiliated Hospital of Guangzhou Medical University1 papers (2020–2020)Junmin Lee · Pohang University of Science and Technology1 papers (2019–2019)Prakash Sampath · Brown University1 papers (2014–2014)Xingwu Zhou · University of Michigan1 papers (2020–2020)Kalpana Ravi · Massachusetts Institute of Technology1 papers (2021–2021)Moyuan Qu · Stomatology Hospital1 papers (2020–2020)